Welcome to the Initiative for Theranostics and Particle Therapy (ITPT), a joint initiative of UW Carbone Cancer Center, UW School of Medicine and Public Health, Wisconsin Alumni Research Foundation and UW Health to strengthen existing research collaborations, create new partnerships and resources, and drive innovative treatments for metastatic cancer patients in Wisconsin and worldwide.
ITPT unites the efforts of researchers whose specialties include targeted radionuclide therapy (TRT) discovery and development, radiobiology, translational radiotherapy, medical physics, advanced imaging, personalized dosimetry, and radio-immunotherapy combinations. In addition to cross-training and educational goals, ITPT resources will support preclinical, translational and clinical research to advance new precision radiopharmaceutical development.
Leveraging our initiative’s vast expertise in radiopharmaceutical development, immunobiology and therapy, dosimetry, and radiation biology and therapy, along with commitments to significantly expand our UW offerings in theranostics, scientists and physicians across multiple disciplines have established the UW Initiative for Theranostics and Particle Therapy (ITPT). The mission of this initiative is to establish and maintain world class programs for theranostics and particle therapy research and education and to provide highest quality personalized treatment for patients with cancer.
Bringing Discovery to Patients
The new Eastpark Medical Center (est. fall of 2024) will significantly expand current clinical offerings including 4 theranostic nuclear medicine patient suites, scanners, and a new proton radiotherapy system.
Radiopharmaceutical Analytics and Specimen Research (RASR) laboratory,
ITPT oversees the Radiopharmaceutical Analytics and Specimen Research (RASR) laboratory, located on the 5th floor of the Clinical Sciences Building, between the WIMR towers and UWHC. RASR will enable UWCCC researchers and external partners to store and analyze radioactive tissue samples and thoroughly examine the in vivo metabolism and biology of radiopharmaceuticals. The operational aim of the RASR is to harbor all radioactive analyses within the ITPT in order to streamline regulatory requirements and compliance while maximizing safety. RASR is a secure facility with access limited to approved researchers and staff. RASR equipment that enables state-of-the-art immunophenotyping of radioactive blood and tissues specimens. Equipment includes freezers (-80°C and -20°C), refrigerators, BSL2 biosafety cabinet, chemical safety hood, incubators with CO2, tabletop centrifuge, microcentrifuges, tissue disaggregators (used for isolating immune cells from tumor), a Leica CM1950 Cryostat for tissue sectioning, and the following unique devices.
- Shimadzu LC-20 HPLC system
- IsoPlexis DuoSpark
- ThermoFisher Attune Nxt Flow Cytometer
- 10X Genomics Chromium iX
- 10X Genomics Visium CytAssist
- Hidex automated gamma counter and liquid scintillation counter